Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression–free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

Recent studies suggest CD133, a surface protein widely used for isolation of colon cancer stem cells, to be associated with tumor angiogenesis and recurrence. We hypothesized that gene expression levels and germline variations in CD133 will predict clinical outcome in patients with mCRC, treated in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pohl, Alexandra, El-Khoueiry, Anthony, Yang, Dongyun, Zhang, Wu, Lurje, Georg, Ning, Yan, Winder, Thomas, Hu-Lieskoven, Siwen, Iqbal, Sima, Danenberg, Kathleen D., Kahn, Michael, Teo, Jia-Ling, Shriki, Jabi, Stebbing, Justin, Lenz, Heinz-Josef
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3326190/
https://ncbi.nlm.nih.gov/pubmed/22231565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2011.61
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge